{"denoms":[{"counts":[{"groupId":"BG000","value":"355"},{"groupId":"BG001","value":"357"},{"groupId":"BG002","value":"712"}],"units":"Participants"}],"groups":[{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, beginning in cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\\> \\> Atezolizumab: Given IV\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Fluorouracil: Given IV\\>\n\n\\> Leucovorin Calcium: Given IV\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Oxaliplatin: Given IV\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"BG000","title":"Arm I (Combination Chemotherapy, Atezolizumab)"},{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Fluorouracil: Given IV\\>\n\n\\> Leucovorin Calcium: Given IV\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Oxaliplatin: Given IV\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"BG001","title":"Arm II (Combination Chemotherapy)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"50","upperLimit":"72","value":"64"},{"groupId":"BG001","lowerLimit":"47","upperLimit":"72","value":"63"},{"groupId":"BG002","lowerLimit":"49","upperLimit":"72","value":"64"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"206"},{"groupId":"BG002","value":"392"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"169"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"320"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"46"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"322"},{"groupId":"BG001","value":"320"},{"groupId":"BG002","value":"642"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"24"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"22"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"50"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"302"},{"groupId":"BG001","value":"305"},{"groupId":"BG002","value":"607"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"27"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"341"},{"groupId":"BG001","value":"343"},{"groupId":"BG002","value":"684"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"28"}]}],"title":"Germany"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"463"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"127"},{"groupId":"BG002","value":"238"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}],"title":"2"}]}],"description":"0 Fully active, able to carry on all pre-disease performance without restriction\\>\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\\>\n2. Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours\\>\n3. Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours\\>\n4. Completely disabled; cannot carry on any selfcare; totally confined to bed or chair\\>\n5. Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}]}